Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)

Conditions: Borderline Resectable Pancreatic Cancer Interventions: Drug: Pembrolizumab Sponsors: Amsterdam UMC, location VUmc; Maastricht University Medical Center; Erasmus Medical Center; St. Antonius Hospital Not yet recruiting

https://clinicaltrials.gov/study/NCT06384560

Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials